Condition: Limited Stage Small Cell Lung Cancer · Sponsor: Pharmacosmos A/S
The goal of this clinical trial is to compare the efficacy and safety of trilaciclib versus placebo in subjects with limited stage small cell lung cancer. The main question it aims to answer is: Does trilaciclib have a myeloprotective effect in subject with limited stage small cell lung cancer? Participants will be randomised to receive either trilaciclib or placebo.
This description comes directly from the study's public registry record.
Pharmacosmos A/S Clinical and non-clinical research · +4559485959 · info@pharmacosmos.com
Always discuss trial participation with your own doctor first.
| Pharmacosmos Investigational Site | Oakland, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07473128